Chronic treatment with a serotonin2 receptor (5-HT2R) agonist modulates the behavioral and cellular response to (+)-3,4- methylenedioxymethamphetamine [(+)-MDMA]

Julie D. Ross, David V. Herin, Paul S. Frankel, Mary L. Thomas, Kathryn Cunningham

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

3,4-Methylenedioxymethamphetamine [MDMA; ecstasy] evokes a multifaceted subjective experience in human users which includes stimulation, feelings of well-being, mood elevation, empathy towards others as well as distortions in time, sensation and perception. Aspects of this unique psychopharmacology of MDMA are thought to be related to its potent actions to release serotonin (5-HT) and indirectly stimulate the 5-HT2A receptor (5-HT2AR). In the present studies, we examined the interrelationship between down-regulation of 5-HT2AR expression and the behaviorally stimulatory effects generated by acute administration of (+)-MDMA, the most potent enantiomer of (±)-MDMA. Male Sprague-Dawley rats were chronically treated with the preferential 5-HT2AR agonist 2,5-dimethoxy-4- iodoamphetamine (DOI) which has been shown to down-regulate expression of the 5-HT2AR, but not the closely related 5-HT2CR. While chronic DOI treatment did not alter the functional sensitivity of either the 5-HT2AR or 5-HT2CR, this regimen enhanced (+)-MDMA-evoked hyperactivity. Subsequent analysis of c-Fos and 5-HT2AR immunoreactivity in brain sections demonstrated that DOI treatment decreased the number of (+)-MDMA-induced c-Fos immunopositive nuclei and 5-HT2AR immunostaining in select cortical and striatal areas. These results indicate that chronic DOI exposure results in an enhanced behavioral response to (+)-MDMA and in a pattern of neuronal activation which resembles that seen in psychostimulant sensitization. These data also suggest that expression of the 5-HT2AR in the NAc and PFC may play a role in the sensitivity to the locomotor-stimulating effects of (+)-MDMA and in the processes of neural regulation upon repeated psychostimulant administration.

Original languageEnglish (US)
Pages (from-to)117-127
Number of pages11
JournalDrug and Alcohol Dependence
Volume81
Issue number2
DOIs
StatePublished - Feb 1 2006

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Receptor, Serotonin, 5-HT2A
sensitization
regulation
empathy
mood
activation
brain
well-being
Therapeutics
experience
Serotonin
Down-Regulation
Serotonin 5-HT2 Receptor Agonists
Time Perception
Corpus Striatum
Psychopharmacology
Enantiomers
Sprague Dawley Rats
Rats

Keywords

  • DOI
  • Hyperactivity
  • MDMA
  • MK 212
  • Sensitization
  • Serotonin receptor

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Chronic treatment with a serotonin2 receptor (5-HT2R) agonist modulates the behavioral and cellular response to (+)-3,4- methylenedioxymethamphetamine [(+)-MDMA]. / Ross, Julie D.; Herin, David V.; Frankel, Paul S.; Thomas, Mary L.; Cunningham, Kathryn.

In: Drug and Alcohol Dependence, Vol. 81, No. 2, 01.02.2006, p. 117-127.

Research output: Contribution to journalArticle

@article{291909a1d1f845cea21f1c7440ac958e,
title = "Chronic treatment with a serotonin2 receptor (5-HT2R) agonist modulates the behavioral and cellular response to (+)-3,4- methylenedioxymethamphetamine [(+)-MDMA]",
abstract = "3,4-Methylenedioxymethamphetamine [MDMA; ecstasy] evokes a multifaceted subjective experience in human users which includes stimulation, feelings of well-being, mood elevation, empathy towards others as well as distortions in time, sensation and perception. Aspects of this unique psychopharmacology of MDMA are thought to be related to its potent actions to release serotonin (5-HT) and indirectly stimulate the 5-HT2A receptor (5-HT2AR). In the present studies, we examined the interrelationship between down-regulation of 5-HT2AR expression and the behaviorally stimulatory effects generated by acute administration of (+)-MDMA, the most potent enantiomer of (±)-MDMA. Male Sprague-Dawley rats were chronically treated with the preferential 5-HT2AR agonist 2,5-dimethoxy-4- iodoamphetamine (DOI) which has been shown to down-regulate expression of the 5-HT2AR, but not the closely related 5-HT2CR. While chronic DOI treatment did not alter the functional sensitivity of either the 5-HT2AR or 5-HT2CR, this regimen enhanced (+)-MDMA-evoked hyperactivity. Subsequent analysis of c-Fos and 5-HT2AR immunoreactivity in brain sections demonstrated that DOI treatment decreased the number of (+)-MDMA-induced c-Fos immunopositive nuclei and 5-HT2AR immunostaining in select cortical and striatal areas. These results indicate that chronic DOI exposure results in an enhanced behavioral response to (+)-MDMA and in a pattern of neuronal activation which resembles that seen in psychostimulant sensitization. These data also suggest that expression of the 5-HT2AR in the NAc and PFC may play a role in the sensitivity to the locomotor-stimulating effects of (+)-MDMA and in the processes of neural regulation upon repeated psychostimulant administration.",
keywords = "DOI, Hyperactivity, MDMA, MK 212, Sensitization, Serotonin receptor",
author = "Ross, {Julie D.} and Herin, {David V.} and Frankel, {Paul S.} and Thomas, {Mary L.} and Kathryn Cunningham",
year = "2006",
month = "2",
day = "1",
doi = "10.1016/j.drugalcdep.2005.06.004",
language = "English (US)",
volume = "81",
pages = "117--127",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Chronic treatment with a serotonin2 receptor (5-HT2R) agonist modulates the behavioral and cellular response to (+)-3,4- methylenedioxymethamphetamine [(+)-MDMA]

AU - Ross, Julie D.

AU - Herin, David V.

AU - Frankel, Paul S.

AU - Thomas, Mary L.

AU - Cunningham, Kathryn

PY - 2006/2/1

Y1 - 2006/2/1

N2 - 3,4-Methylenedioxymethamphetamine [MDMA; ecstasy] evokes a multifaceted subjective experience in human users which includes stimulation, feelings of well-being, mood elevation, empathy towards others as well as distortions in time, sensation and perception. Aspects of this unique psychopharmacology of MDMA are thought to be related to its potent actions to release serotonin (5-HT) and indirectly stimulate the 5-HT2A receptor (5-HT2AR). In the present studies, we examined the interrelationship between down-regulation of 5-HT2AR expression and the behaviorally stimulatory effects generated by acute administration of (+)-MDMA, the most potent enantiomer of (±)-MDMA. Male Sprague-Dawley rats were chronically treated with the preferential 5-HT2AR agonist 2,5-dimethoxy-4- iodoamphetamine (DOI) which has been shown to down-regulate expression of the 5-HT2AR, but not the closely related 5-HT2CR. While chronic DOI treatment did not alter the functional sensitivity of either the 5-HT2AR or 5-HT2CR, this regimen enhanced (+)-MDMA-evoked hyperactivity. Subsequent analysis of c-Fos and 5-HT2AR immunoreactivity in brain sections demonstrated that DOI treatment decreased the number of (+)-MDMA-induced c-Fos immunopositive nuclei and 5-HT2AR immunostaining in select cortical and striatal areas. These results indicate that chronic DOI exposure results in an enhanced behavioral response to (+)-MDMA and in a pattern of neuronal activation which resembles that seen in psychostimulant sensitization. These data also suggest that expression of the 5-HT2AR in the NAc and PFC may play a role in the sensitivity to the locomotor-stimulating effects of (+)-MDMA and in the processes of neural regulation upon repeated psychostimulant administration.

AB - 3,4-Methylenedioxymethamphetamine [MDMA; ecstasy] evokes a multifaceted subjective experience in human users which includes stimulation, feelings of well-being, mood elevation, empathy towards others as well as distortions in time, sensation and perception. Aspects of this unique psychopharmacology of MDMA are thought to be related to its potent actions to release serotonin (5-HT) and indirectly stimulate the 5-HT2A receptor (5-HT2AR). In the present studies, we examined the interrelationship between down-regulation of 5-HT2AR expression and the behaviorally stimulatory effects generated by acute administration of (+)-MDMA, the most potent enantiomer of (±)-MDMA. Male Sprague-Dawley rats were chronically treated with the preferential 5-HT2AR agonist 2,5-dimethoxy-4- iodoamphetamine (DOI) which has been shown to down-regulate expression of the 5-HT2AR, but not the closely related 5-HT2CR. While chronic DOI treatment did not alter the functional sensitivity of either the 5-HT2AR or 5-HT2CR, this regimen enhanced (+)-MDMA-evoked hyperactivity. Subsequent analysis of c-Fos and 5-HT2AR immunoreactivity in brain sections demonstrated that DOI treatment decreased the number of (+)-MDMA-induced c-Fos immunopositive nuclei and 5-HT2AR immunostaining in select cortical and striatal areas. These results indicate that chronic DOI exposure results in an enhanced behavioral response to (+)-MDMA and in a pattern of neuronal activation which resembles that seen in psychostimulant sensitization. These data also suggest that expression of the 5-HT2AR in the NAc and PFC may play a role in the sensitivity to the locomotor-stimulating effects of (+)-MDMA and in the processes of neural regulation upon repeated psychostimulant administration.

KW - DOI

KW - Hyperactivity

KW - MDMA

KW - MK 212

KW - Sensitization

KW - Serotonin receptor

UR - http://www.scopus.com/inward/record.url?scp=29244482574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244482574&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2005.06.004

DO - 10.1016/j.drugalcdep.2005.06.004

M3 - Article

C2 - 16054778

AN - SCOPUS:29244482574

VL - 81

SP - 117

EP - 127

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 2

ER -